Scancell Holdings (GB:SCLP) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scancell Holdings Plc, a developer of novel immunotherapies, has received positive feedback from a panel of melanoma experts on its Phase 2/3 SCOPE study plans for treating cancer. The study, which is currently recruiting patients, is expected to present clinical results in late 2024 and early 2025. This milestone follows a successful presentation at ASCO, where Scancell’s clinical data received significant attention.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.